Přeskočit navigaci Úvodní stránka O projektu Redakční rada Kontakt Informace pro média Napsali o nás RSS
 
Přeskočit navigaci
 

30th ASBMR 2008

[M361] Postmenopausal Women With Gastroesophageal Reflux Disease and Long Term Treatment With Bisphosphonates IV

Miro Cokolic.. UKC Maribor.

The aim of this study was to assess the effectiveness of bisphosphonate (BP) iv (zolendronat 5 mg, pamidronate 30 mg, ibandronate 3 mg) therapy in treatment of postmenopausal osteoporosis in patients with gastroesophageal reflux disease (GERD). GERD occurs when the lower esophageal sphincter opens spontaneously, for varying periods of time, or does not close properly and stomach contents rise up into the esophagus and it can eventually lead to more serious health problems and unable take BP oraly.
Fifteen women with osteoporosis (T-score at lumbar spine or hip <-2.5 SD) were enrolled in a prospective study between January 2003 and December 2007. Patients were 61 to 93 years old (mean: 72,3 years). They were treated with BP iv in combination with 500-mg elemental calcium and 800 IU vitamin D. The BMD in the lumbar spine (L1-L4) and left hip was measured in all patients using dual energy X-ray densitometry (Hologic 2000+) at the start of the treatment and at 12 to 48 months after initiation of the treatment. The serum levels of RBC, Hgb, WBC, Plt, TSH, Ca, P, Mg, Na, K, Cl, ALP, AST, ALT, BUN, creatinine, osteocalcin and ß cross laps were measured every 12 months. Average baseline BMD was 0.698 g/cm2 (n=15, range 0.602 to 0.787 g/cm2) at the lumbar spine and 0.676 g/ cm2 (n=15, range 0.499 to 0.862 g/cm2) at the hip.
After treating patients on average for 40 months, the average BMD was 0.722 g/cm2 (n=15, range 0.600 to 0.966 g/cm2) at the lumbar spine and 0.704 g/ cm2 (n=15, range 0.494 to 0.901 g/cm2) at the hip. BMD thus increased on average by 3.4% at the lumbar spine and 4.1% at the hip. Serum levels remained within normal limits throughout the treatment, with no adverse events observed during the study. BF iv was well tolerated in all patients.
In our report of our on-going study we have shown that postmenopausal osteoporosis with GERD can be effectively and safely treated with BF iv in all patients for up to four years without new fractures.

M. Cokolic, None.

Date: Monday, September 15, 2008
Session Info: Poster: Osteoporosis Treatment (Clinical): Bisphosphonates (11:30 AM-2:30 PM)
Presentation Time: 11:30 AM


Buďte první a přidejte svůj komentář k článku!

archiv

Osteoporosis Clinical Updates

 

Diagnostika a léčba osteoporózy u osob vyššího věku v Austrálii Diagnostika a léčba osteoporózy u osob vyššího věku v Austrálii

V časopise Australian Family Physician vyšel v březnu 2012 velmi praktický článek o epidemiologii, diagnostice a léčbě osteoporózy u starších pacientů. Obsah článku může být přínosem i pro české praktické lékaře, kteří se s rizikovými pacienty ve své praxi běžně setkávají.

Ve studii Geelong Osteoporosis study u osob nad 80 let byla osteoporóza (T-skóre –2,5 a nižší) zjištěna u 51 % žen a 19 % mužů. Populační studie provedená v Sydney uvádí, že kritéria pro farmakologickou léčbu osteoporózy splňuje 25 % mužů nad 70 let, z nichž 90 % neví, že má osteoporózu. Doživotní riziko vzniku osteoporotické zlomeniny u osob nad 60 let je asi 56 % u žen a 29 % u mužů. Výskyt nízkoenergetické zlomeniny zvyšuje podle Dubbo Osteoporosis Epidemiology Study riziko další zlomeniny v následujících 10 letech a je spojen se zvýšenou mortalitou. Farmakoterapii u osteoporózy užívá v Austrálii méně než 30 % žen se zlomeninou po menopauze a pouze 10 % mužů s osteoporózou.

Spustit